Table 3.
Clinical measures at baseline and on V-Go based on change in concomitant anti-hyperglycemic medications
| Clinical measure | Initiation of V-Go+ | ||
|---|---|---|---|
| No change in anti-hyperglycemic medication(s) (n = 110) | Increase in anti-hyperglycemic medication(s) (n = 43) | Decrease in anti-hyperglycemic medication(s) (n = 39) | |
| HbA1c (%) | |||
| Baseline | 9.48 (9.22–9.74) | 10.04 (9.62–10.46) | 9.35 (8.91–9.79) |
| On V-Go | 8.09 (7.83–8.35) | 8.08 (7.66–8.50) | 8.03 (7.59–8.47) |
| Insulin TDD (U/day) | |||
| Baseline | 80 (74–86) | 112* (102–123) | 65 (54–77) |
| On V-Go | 56 (50–62) | 68 (58–78) | 53 (43–64) |
| Weight (kg) | |||
| Baseline | 93 (89–97) | 105* (99–111) | 93 (87–100) |
| On V-Go | 94 (90–98) | 107* (101–114) | 95 (89–102) |
Data are least-squares mean with corresponding 95% confidence intervals derived from a repeated measures mixed model based on 14-week results. Baseline insulin TDD reflects prescribed lower limit TDD. Only those changes in concomitant anti-hyperglycemic medication(s) providing sufficient time for clinical effect were categorized as an increase or decrease
HbA1c glycated hemoglobin, TDD total daily dose
* P < 0.01 compared to same measure for both no change and decrease in concomitant anti-hyperglycemic medication(s)